60 Degrees Pharmaceuticals Enters and Terminates Agreements

TL;DR

60 Degrees Pharma just signed and broke a big deal. What's next?

AI Summary

On September 3, 2025, 60 Degrees Pharmaceuticals, Inc. entered into a material definitive agreement and also terminated a material definitive agreement. The company, incorporated in Delaware with its principal office in Washington D.C., filed this 8-K report detailing these events.

Why It Matters

This filing indicates significant corporate actions, including both the initiation and cessation of material agreements, which could impact the company's strategic direction and financial performance.

Risk Assessment

Risk Level: medium — The simultaneous entry into and termination of material definitive agreements suggests potential volatility or strategic shifts within the company.

Key Numbers

• 001-41719 — SEC File Number (Identifies the company's filing with the SEC.)
• 45-2406880 — IRS Employer Identification Number (Company's tax identification number.)

Key Players & Entities

• 60 Degrees Pharmaceuticals, Inc. (company) — Registrant
• September 3, 2025 (date) — Date of earliest event reported
• Delaware (jurisdiction) — State of Incorporation
• Washington D.C. (location) — Business Address City

FAQ

Key Financial Figures

• $0.0001 — ch registered Common Stock, par value $0.0001 per share SXTP The Nasdaq Stock Mar
• $1,397,533 — aggregate gross sales proceeds of up to $1,397,533 (the "ATM Offering"), through or to Wai

Filing Documents

• ea0255916-8k_60degrees.htm (8-K) — 33KB
• ea025591601ex1-1_60degrees.htm (EX-1.1) — 197KB
• ea025591601ex5-1_60degrees.htm (EX-5.1) — 7KB
• image_001.jpg (GRAPHIC) — 6KB
• 0001213900-25-085040.txt ( ) — 507KB
• sxtp-20250903.xsd (EX-101.SCH) — 4KB
• sxtp-20250903_def.xml (EX-101.DEF) — 26KB
• sxtp-20250903_lab.xml (EX-101.LAB) — 36KB
• sxtp-20250903_pre.xml (EX-101.PRE) — 25KB
• ea0255916-8k_60degrees_htm.xml (XML) — 6KB

01 Entry into a Material

Item 1.01 Entry into a Material Definitive Agreement. On September 3, 2025, 60 Degrees Pharmaceuticals, Inc. (the "Company") entered into an At-The-Market Sales Agreement (the "Sales Agreement") with H.C. Wainwright & Co., LLC ("Wainwright") pursuant to which the Company may, from time to time, offer and sell shares (the "ATM Shares") of its common stock, par value $0.0001 per share (the "Common Stock"), having aggregate gross sales proceeds of up to $1,397,533 (the "ATM Offering"), through or to Wainwright, acting as sales agent or principal, subject to the Company's current "baby shelf" limitations under General Instruction I.B.6. of Form S-3. Agreement, Wainwright will use its commercially reasonable efforts consistent with its normal trading and sales practices to sell the ATM Shares from time to time, based upon the Company's instructions. The Company has provided Wainwright with customary indemnification and contribution rights in favor of the Agents, and the Wainwright will be entitled to a commission of 3.0% of the gross proceeds from each sale of the ATM Shares pursuant to the Sales Agreement. Sales of the ATM Shares, if any, under the Agreement will be made by any method permitted by law deemed to be "at the market offerings" as defined in Rule 415 under the Securities Act of 1933, as amended (the "Securities Act"). The Company has no obligation to sell any of the ATM Shares and may at any time suspend offers under the Sales Agreement or terminate the Sales Agreement. This description of the Sales Agreement does not purport to be complete and is qualified in its entirety by reference to the Sales Agreement, which is attached hereto as Exhibit 1.1 and incorporated by reference herein. The Company Common Stock to be sold under the Sales Agreement, if any, will be issued and sold pursuant to the Company's shelf registration statement on Form S-3 (File No. 333-280796), which was filed with the Securities a

02 Termination of a Material Definitive Agreement

Item 1.02 Termination of a Material Definitive Agreement. On September 3, 2025, 60 Degrees Pharmaceuticals, Inc. (the "Company") and Wallachbeth Capital LLC ("Wallachbeth") entered into a Waiver and Termination Agreement of the At-The-Market Issuance Sales Agreement, dated June 4, 2024 (the "ATM Agreement"). The Company and Wallachbeth agreed to waive the 10-day notice termination period (the "Notice Termination Period"), and the Company exercised its right to the immediate termination of the ATM Agreement, effective as of September 3, 2025, and both parties were released from any obligations under the ATM Agreement as of the same date.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits (a) Exhibits Number Description 1.1 Sales Agreement, dated as of September 5, 2025, by and among the 60 Degree Pharmaceuticals, Inc. and H.C. Wainwright & Co., LLC, 5.1 Opinion of Sichenzia Ross Ference Carmel LLP 23.1 Consent of Sichenzia Ross Ference Carmel LLP (included in the opinion filed as Exhibit 5.1) 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) 1

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. 60 DEGREES PHARMACEUTICALS, INC. Date: September 5, 2025 By: /s/ Geoffrey Dow Name: Geoffrey Dow Title: Chief Executive Officer and President 2

View Full Filing

View this 8-K filing on SEC EDGAR